

DR CATHERINE MOHR TO JOIN AROA BOARD

Aroa Biosurgery Limited (ASX: ARX, 'AROA' or the 'Company'), a soft tissue regeneration company with over 5 million devices applied to date in treating patients worldwide, is pleased to announce the appointment of Dr. Catherine Mohr as a Non-Executive Director of the Company.

Dr. Mohr brings a breadth of skills and experience to the AROA Board. She is a seasoned medtech executive who was most recently at industry leader Intuitive Surgical, Inc., a long-time entrepreneur, and was previously a consulting assistant professor at the Stanford University School of Medicine's Department of Surgery.

Born in New Zealand, Dr. Mohr's background spans several key areas of expertise related to AROA's next stage of growth, including medtech product research and development, US Food & Drug Administration approvals, product commercialization and surgery technology innovation.

Dr. Mohr has lived in the United States for many years and received her Bachelor of Science and Master's in Mechanical Engineering from Massachusetts Institute of Technology, and her Doctor of Medicine from the Stanford University School of Medicine.

Dr. Mohr has been involved with several successful emerging companies, notably co-founding VeriSure, Inc. where she invented the LapCap™, the first of a new category of laparoscopic surgery enabling products. She is currently a director on the board of Finca International, a non-profit organization focused on alleviating poverty through lasting solutions.

Dr. Mohr has been the President of the Intuitive Foundation, the corporate Foundation of Silicon Valley-based Intuitive Surgical, since 2018. Intuitive Surgical is a pioneer in the robotic-assisted surgery field and developed the da Vinci surgical robotic system which is used in millions of surgical procedures across the globe every year.

Prior to heading up the Foundation, Dr. Mohr was a key member of the Intuitive Surgical management team for over 12 years. Beginning her tenure in 2006, Dr Mohr held several senior roles, including Vice President of Strategy and Director of Medical Research, making a significant contribution to the organisation's growth.

AROA CEO Dr. Brian Ward says, "Dr. Mohr's diverse skillset and considerable research and development experience are immense assets to AROA. We are delighted to welcome her guidance to support us in our mission to unlock regenerative healing for *everybody*".

Dr. Ward's sentiments are echoed by Board Chairman Jim McLean who says: "We welcome the broad international experience and valuable insights Dr. Mohr brings to AROA's Board".

Dr. Mohr's appointment to the Board is targeted to take effect from 1 November 2022, following completion of Australian law director identification number requirements. Dr. Mohr will stand for election by shareholders at AROA's next Annual Meeting in or around August 2023.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.



About AROA™

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. AROA's products have been used in more than four and a half million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroabio.com

Contact

Sarah Tora
Corporate Communications Manager, Aroa Biosurgery
+64 (0) 21 531 043
Sarah.tora@aroabio.com